Cubist seeks U.S. approval for trials of 2 antibiotics

01/6/2009 | Boston Globe (tiered subscription model), The

Cubist Pharmaceuticals asked the FDA to allow clinical studies of two treatments for bacterial infections. Cubist said it is developing two lipopeptides -- CB-182,804 for drug-resistant Gram-negative bacteria and CB-183,315 for diarrhea linked to Clostridium difficile.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC